Online citations, reference lists, and bibliographies.
← Back to Search

Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical T

R. Gill, A. Tsao, H. Kindler, W. Richards, S. Armato, R. Francis, D. Gomez, S. Dahlberg, A. Rimner, C. Simone, M. D. de Perrot, G. Blumenthal, A. Adjei, R. Bueno, D. Harpole, M. Hesdorffer, F. Hirsch, H. Pass, E. Yorke, K. Rosenzweig, B. Burt, D. A. Fennell, Wolf Lindwasser, S. Malik, T. Peikert, A. Mansfield, R. Salgia, H. Yang, V. Rusch, A. Nowak
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma (MPM) are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously and lack of specific recommendations within the radiology community about assessment, reporting and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute (NCI) Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer (IASLC), and the Mesothelioma Applied Research Foundation (MARF). One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of MPM in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting and response assessment within clinical trials.
This paper references
10.1053/SONC.2002.30228
The role of imaging in malignant pleural mesothelioma.
E. Marom (2002)
10.1007/s00259-013-2561-1
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma
A. Klabatsa (2013)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
10.1053/j.semtcvs.2009.06.011
Current trends in radiologic management of malignant pleural mesothelioma.
R. Gill (2009)
10.1016/J.ATHORACSUR.2005.06.014
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
D. Rice (2005)
10.1007/s00259-017-3687-3
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
K. Pinker (2017)
10.1007/BF02305768
Laparoscopy: An important tool in the staging of malignant pleural mesothelioma
K. Conlon (2006)
10.1038/srep31745
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment
P. Lizotte (2016)
10.1016/j.jtho.2016.09.124
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
V. Rusch (2016)
10.1002/jso.25241
Success of genomic profiling of non–small cell lung cancer biopsies obtained by trans‐thoracic percutaneous needle biopsy
R. Gill (2018)
10.1016/J.LUNGCAN.2005.03.007
The role of PET in the surgical management of malignant pleural mesothelioma.
R. Flores (2005)
10.1016/j.jtho.2016.04.027
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
10.1016/J.JTCVS.2005.02.051
Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy.
J. Alvarez (2005)
10.1016/S0169-5002(03)00292-7
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
10.1016/j.jtho.2018.08.2036
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
A. Tsao (2018)
10.1007/s00259-017-3853-7
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems
Andres Kaalep (2017)
10.1016/j.lungcan.2018.01.014
Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy
S. Tsim (2018)
10.1016/j.athoracsur.2016.06.069
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
V. Rusch (2016)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
10.1097/JTO.0b013e318208c83d
A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria
A. Tsao (2011)
10.1183/13993003.01428-2016
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.1016/j.mayocp.2018.01.032
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma
A. Mansfield (2018)
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.
D. Delbeke (2006)
10.1016/j.acra.2007.12.014
Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34).
F. Giesel (2008)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1016/j.cpet.2011.04.001
Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging.
V. Gerbaudo (2011)
10.1016/J.JTHO.2018.08.276
OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
A. Nowak (2018)
10.2214/AJR.164.3.7863875
Interventional radiology of the chest: image-guided percutaneous drainage of pleural effusions, lung abscess, and pneumothorax.
J. Klein (1995)
10.1148/RG.241035058
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
10.1007/s00259-014-2961-x
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
R. Boellaard (2014)
10.1016/j.ctrv.2011.01.001
Advances in the biology of malignant pleural mesothelioma.
P. Zucali (2011)
10.1016/J.CTRV.2007.07.012
Assessment of tumor response in malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1016/j.mric.2008.03.004
MR imaging of benign and malignant pleural disease.
R. Gill (2008)
10.1097/PAS.0000000000000134
Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease
Kyuichi Kadota (2014)
10.1016/S1470-2045(18)30765-4
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel (2019)
10.2214/AJR.09.3519
Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
R. Gill (2010)
10.1259/bjr.20170814
18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
H. S. Elliott (2018)
10.1200/JOP.17.00012
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary.
H. Kindler (2018)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
10.1093/jnci/djx175
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma
R. Gill (2018)
10.1097/00005382-199710000-00002
Transthoracic Needle Biopsy: An Overview
J. Klein (1997)
10.1097/JTO.0b013e31828354c8
Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma
Z. Labby (2013)
10.1016/J.EJRAD.2007.08.010
Morphologic and functional imaging of malignant pleural mesothelioma.
M. Yamamuro (2007)
10.2967/jnumed.108.057307
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
R. Wahl (2009)
10.1016/S1470-2045(17)30074-8
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
L. Seymour (2017)
10.1148/radiol.2016142043
Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.
J. O (2016)
10.1007/s00259-018-4056-6
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients
E. Incerti (2018)
10.2214/AJR.11.7015
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
R. Gill (2012)
10.1016/j.jtho.2018.04.034
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
S. Armato (2018)
10.1016/j.lungcan.2013.08.005
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
10.1016/j.jtho.2018.05.003
Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race.
A. Tsao (2018)
10.1016/j.lungcan.2015.07.011
Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.
S. Armato (2015)
10.1016/j.jtho.2016.09.121
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
10.1148/radiol.12110872
Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience.
J. Coolen (2012)
10.1007/s00259-014-2960-y
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma
E. Lopci (2014)
10.1016/j.lungcan.2015.08.012
Response evaluation in mesothelioma: Beyond RECIST.
Lin Cheng (2015)



Semantic Scholar Logo Some data provided by SemanticScholar